{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.666.5.2350","meta":{"versionId":"12","lastUpdated":"2016-03-31T01:00:12.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"Lantana EH Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2016-03-31"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2350","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.666.5.2350"}],"version":"20160331","name":"ImmunocompromisedTherapiesI9","title":"Immunocompromised Therapies I9","status":"active","experimental":false,"date":"2016-03-31T01:00:12-04:00","publisher":"Lantana EH Steward","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: This set of values contains procedures for patients who have had  immunocompromising therapies.),(Data Element Scope: The intent of this data element is to identify patients who have had immunocompromising therapies. Using the Quality Data Model, this particular element will map to the Procedure  category.),(Inclusion Criteria: Include codes representing  immunocompromised therapies including systemic chemotherapy, radiation, corticosteroid and other immunosuppressive therapies using  the  ICD 9 CM  code system.),(Exclusion Criteria: None.)","compose":{"include":[{"system":"http://hl7.org/fhir/sid/icd-9-cm","concept":[{"code":"00.10","display":"Implantation of chemotherapeutic agent"},{"code":"00.15","display":"High-dose infusion interleukin-2 [IL-2]"},{"code":"17.70","display":"Intravenous infusion of clofarabine"},{"code":"99.25","display":"Injection or infusion of cancer chemotherapeutic substance"},{"code":"99.28","display":"Injection or infusion of biological response modifier [BRM] as an antineoplastic agent"}]}]},"expansion":{"identifier":"urn:uuid:ce9f47a7-ba57-4307-a56a-0f34b7d5a5ad","timestamp":"2023-12-11T03:11:11-05:00","total":5,"contains":[{"system":"http://hl7.org/fhir/sid/icd-9-cm","version":"2013","code":"00.10","display":"Implantation of chemotherapeutic agent"},{"system":"http://hl7.org/fhir/sid/icd-9-cm","version":"2013","code":"00.15","display":"High-dose infusion interleukin-2 [IL-2]"},{"system":"http://hl7.org/fhir/sid/icd-9-cm","version":"2013","code":"17.70","display":"Intravenous infusion of clofarabine"},{"system":"http://hl7.org/fhir/sid/icd-9-cm","version":"2013","code":"99.25","display":"Injection or infusion of cancer chemotherapeutic substance"},{"system":"http://hl7.org/fhir/sid/icd-9-cm","version":"2013","code":"99.28","display":"Injection or infusion of biological response modifier [BRM] as an antineoplastic agent"}]}}